文献速递脑血管病

SOCRATES试验中替格瑞洛疗效与安全性同随机化前一周内阿司匹林使用的关系

Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial.
PubMed 文献 · Stroke · 2018-06-18

SOCRATES试验预设亚组分析纳入13199例急性缺血性卒中或短暂性脑缺血发作患者,比较替格瑞洛与阿司匹林90天治疗。在随机化前一周内使用过阿司匹林的4232例患者中,替格瑞洛组主要终点事件发生率6.5%,阿司匹林组8.3%(HR 0.76,95%CI 0.61-0.95,P=0.02);治疗与既往阿司匹林使用的交互作用无统计学意义(P=0.10)。

要点

  • 既往阿司匹林组替格瑞洛主要终点事件6.5% vs 阿司匹林8.3%(HR 0.76,95%CI 0.61-0.95,P=0.02)。
  • 无既往阿司匹林组主要终点事件替格瑞洛6.9% vs 阿司匹林7.1%(HR 0.96,95%CI 0.82-1.12,P=0.59)。
  • 治疗与既往阿司匹林使用的交互作用无统计学意义(P=0.10)。

核心结论

  • 在随机化前接受阿司匹林的患者中,替格瑞洛治疗的主要终点事件少于阿司匹林,但治疗与既往阿司匹林使用无显著交互作用。
  • 一项新研究将探讨替格瑞洛联合阿司匹林在急性脑缺血患者中的获益-风险(NCT03354429)。

研究设计与样本

  • SOCRATES试验的预设亚组分析,共纳入13199例急性缺血性卒中(NIHSS评分≤5)或短暂性脑缺血发作(ABCD2评分≥4)患者。
  • 患者随机接受替格瑞洛或阿司匹林治疗90天。
  • 既往阿司匹林组定义为随机化前一周内接受过任何阿司匹林的患者,共4232例。
  • 主要终点为卒中、心肌梗死或死亡的时间;安全性终点为PLATO大出血。

主要发现

  • 既往阿司匹林组中,替格瑞洛组主要终点事件138/2130(6.5%),阿司匹林组177/2102(8.3%),HR 0.76(95%CI 0.61-0.95),P=0.02。
  • 无既往阿司匹林组中,替格瑞洛组主要终点事件304/4459(6.9%),阿司匹林组320/4508(7.1%),HR 0.96(95%CI 0.82-1.12),P=0.59。
  • 治疗与既往阿司匹林使用的交互作用无统计学意义(P=0.10)。
  • 既往阿司匹林组中,替格瑞洛组大出血发生率0.7%,阿司匹林组0.4%,HR 1.58(95%CI 0.68-3.65),P=0.28。
  • 既往阿司匹林组患者较其他患者年龄更大,血管危险因素和血管疾病更多。

关键数值与推荐

  • 急性缺血性卒中患者NIHSS评分≤5,短暂性脑缺血发作患者ABCD2评分≥4。
  • 替格瑞洛与阿司匹林疗程均为90天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% relative risk reduction for stroke, myocardial infarction, or death (P=0.07). Aspirin intake before randomization could enhance the effect of ticagrelor by conferring dual antiplatelet effect during a high-risk period for subsequent stroke. Therefore, we explored the efficacy and safety of ticagrelor versus aspirin in the patients who received any aspirin the week before randomization. METHODS: A prespecified subgroup analysis in SOCRATES (n=13 199), randomizing patients with acute ischemic stroke (National Institutes of Health Stroke Scale score of ≤5) or transient ischemic attack (ABCD2 score of ≥4) to 90-day treatment with ticagrelor or aspirin. Patients in the prior-aspirin group had received any aspirin within the week before randomization. Primary end point was time to stroke, myocardial infarction, or death. Safety end point was PLATO (Study of Platelet Inhibition and Patient Outcomes) major bleeding. RESULTS: The 4232 patients in the prior-aspirin group were older, had more vascular risk factors, and vascular disease than the other patients. In the prior-aspirin group, the primary end point occurred in 138/2130 (6.5%) of patients on ticagrelor and in 177/2102 (8.3%) on aspirin (hazard ratio, 0.76; 95% confidence interval, 0.61-0.95; P=0.02); in patients with no prior-aspirin usage an event occurred in 304/4459 (6.9%) and 320/4508 (7.1%) on ticagrelor and aspirin, respectively (hazard ratio, 0.96; 95% confidence interval, 0.82-1.12; P=0.59). The treatment-by-prior-aspirin interaction was not statistically significant (P=0.10). In the prior-aspirin group, major bleeding occurred in 0.7% and 0.4% of patients on ticagrelor and aspirin, respectively (hazard ratio, 1.58; 95% confidence interval, 0.68-3.65; P=0.28). CONCLUSIONS: In this secondary analysis from SOCRATES, fewer primary end points occurred on ticagrelor treatment than on aspirin in patients receiving aspirin before randomization, but there was no significant treatment-by-prior-aspirin interaction. A new study will investigate the benefit-risk of combining ticagrelor and aspirin in patients with acute cerebral ischemia (URL: https://www.clinicaltrials.gov. Unique identifier: NCT03354429). CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01994720.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Wong KSL, Amarenco P, Albers GW, et al. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. Stroke. 2018. PMID: 29915123. doi:10.1161/STROKEAHA.118.020553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。